Sponsors (4)
The bill improves U.S. drug supply security and emergency preparedness—reducing shortages for patients and health systems and boosting domestic manufacturing—while imposing taxpayer costs, creating potential market distortions that could raise prices, and adding regulatory burdens on manufacturers.
Patients (including those with chronic conditions) will have more reliable access to critical medicines because the federal program requires six-month reserves and lets the Secretary direct production to prevent shortages.
The public and federal policymakers gain stronger national preparedness because the program creates an official list of critical drugs/APIs and requires regular reporting to Congress on vulnerabilities and program effectiveness.
Hospitals and health systems will face fewer supply disruptions during public-health emergencies because the Secretary can allocate reserve stock and direct surge production to where it is needed.
Taxpayers will fund the program (including a $500 million FY2026 authorization) and could face additional appropriations to maintain reserves and manufacturing support.
Middle-class families and patients could face higher drug prices or reduced supplier competition if preferences for domestic production disadvantage smaller or non-preferred foreign suppliers.
Small manufacturers and state governments may be burdened by program implementation complexity and regulatory requirements (quality systems, domestic facility registration, surge capacity), which could limit eligible applicants and slow rollout.
Based on analysis of 2 sections of legislative text.
Introduced June 12, 2025 by Gary C. Peters · Last progress June 12, 2025
Creates a new HHS program to contract with drug makers to maintain a rolling reserve of critical active pharmaceutical ingredients (APIs) and finished drug products, with a default six‑month supply held in qualified domestic or OECD‑country facilities. The program will prioritize domestic manufacturing and surge capacity, allow HHS to direct production and allocation during public health emergencies, require interagency coordination and biennial reporting to Congress, and is authorized $500 million for FY2026.